Die prognostische Bedeutung des Nachweises von minimaler Resterkrankung im Krankheitsverlauf bei akuten lymphoblastischen Leukämien im Kindesalter und beim Erwachsenen ist in den letzten Jahren durch mehrere Studien belegt worden. Die Kinetik der Blastenreduktion in der Induktionstherapie hat sich als prognostisch relevant erwiesen und wird in vielen Therapieoptimierungsstudien als ein wesentlicher Parameter für eine risikoadaptierte Therapiestratifikation herangezogen. Derzeit stehen drei hochsensitive und spezifische Methoden für die Detektion von MRD zur Verfügung: Die multiparametrische Durchflußzytometrie (FCM), die Polymerase- Ketten-Reaktion von Fusionsgen Transkripten (RT-PCR) und die RQ-PCR von Leukämie spezifischen klonalen Immung...
Monitoring of minimal residual disease (MRD) has become routine clinical practice in frontline treat...
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatment strategi...
Most current treatment protocols for acute lymphoblastic leukemia (ALL) include minimal residual dis...
Für Patienten mit akuten Leukämien konnte nachgewiesen werden, dass bei Diagnosestellung rund 10^12 ...
Für Patienten mit akuten Leukämien konnte nachgewiesen werden, dass bei Diagnosestellung rund 10^12 ...
The investigation of minimal residual disease (MRD) with multiparameter flow cytometry (FC) immunoph...
Several studies have demonstrated that monitoring of minimal residual disease (MRD) in childhood and...
The investigation of minimal residual disease (MRD) with multiparameter flow cytometry (FC) immunoph...
Traditionally, response to treatment in hematological malignancies is evaluated by light microscopy ...
Traditionally, response to treatment in hematological malignancies is evaluated by light microscopy ...
Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method fo...
AbstractMinimal residual disease is the most powerful predictor of outcome in acute leukemia and is ...
New therapeutic strategies developed recently for chronic lymphocytic leukemia (CLL) have led to rem...
Minimal residual disease (MRD) assessment is a powerful prognostic factor for determining the risk o...
Monitoring of minimal residual disease (MRD) has become routine clinical practice in frontline treat...
Monitoring of minimal residual disease (MRD) has become routine clinical practice in frontline treat...
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatment strategi...
Most current treatment protocols for acute lymphoblastic leukemia (ALL) include minimal residual dis...
Für Patienten mit akuten Leukämien konnte nachgewiesen werden, dass bei Diagnosestellung rund 10^12 ...
Für Patienten mit akuten Leukämien konnte nachgewiesen werden, dass bei Diagnosestellung rund 10^12 ...
The investigation of minimal residual disease (MRD) with multiparameter flow cytometry (FC) immunoph...
Several studies have demonstrated that monitoring of minimal residual disease (MRD) in childhood and...
The investigation of minimal residual disease (MRD) with multiparameter flow cytometry (FC) immunoph...
Traditionally, response to treatment in hematological malignancies is evaluated by light microscopy ...
Traditionally, response to treatment in hematological malignancies is evaluated by light microscopy ...
Multiparametric flow cytometry is an alternative approach to the polymerase chain reaction method fo...
AbstractMinimal residual disease is the most powerful predictor of outcome in acute leukemia and is ...
New therapeutic strategies developed recently for chronic lymphocytic leukemia (CLL) have led to rem...
Minimal residual disease (MRD) assessment is a powerful prognostic factor for determining the risk o...
Monitoring of minimal residual disease (MRD) has become routine clinical practice in frontline treat...
Monitoring of minimal residual disease (MRD) has become routine clinical practice in frontline treat...
Acute lymphoblastic leukemia (ALL) is the most common cancer in children. Current treatment strategi...
Most current treatment protocols for acute lymphoblastic leukemia (ALL) include minimal residual dis...